Compare ESNT & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ESNT | ALKS |
|---|---|---|
| Founded | 2008 | 1987 |
| Country | Bermuda | Ireland |
| Employees | N/A | 1800 |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 5.8B |
| IPO Year | 2013 | 1991 |
| Metric | ESNT | ALKS |
|---|---|---|
| Price | $63.94 | $34.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 13 |
| Target Price | ★ $68.71 | $42.85 |
| AVG Volume (30 Days) | 757.1K | ★ 2.2M |
| Earning Date | 02-13-2026 | 02-13-2026 |
| Dividend Yield | ★ 1.90% | N/A |
| EPS Growth | N/A | ★ 2.44 |
| EPS | ★ 6.87 | 2.02 |
| Revenue | $1,263,558,000.00 | ★ $1,521,338,000.00 |
| Revenue This Year | $3.55 | N/A |
| Revenue Next Year | $1.24 | $23.22 |
| P/E Ratio | ★ $9.50 | $17.34 |
| Revenue Growth | ★ 2.04 | 1.08 |
| 52 Week Low | $51.61 | $25.17 |
| 52 Week High | $67.09 | $36.45 |
| Indicator | ESNT | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 53.09 | 64.06 |
| Support Level | $60.92 | $33.35 |
| Resistance Level | $66.36 | $35.02 |
| Average True Range (ATR) | 1.29 | 1.18 |
| MACD | 0.35 | 0.01 |
| Stochastic Oscillator | 59.09 | 82.98 |
Essent Group Ltd serves the housing finance industry by providing private mortgage insurance, reinsurance, risk management products, title insurance, and settlement services to mortgage lenders, borrowers, and investors to support homeownership. It provides credit protection to lenders and mortgage investors by covering a portion of the unpaid principal balance of a mortgage and certain related expenses in the event of a default. By providing capital to mitigate mortgage credit risk, the company allows lenders to make additional mortgage financing available to prospective homeowners.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.